Research Support Centre
Technology Platforms

Model-based Digital Pathology Solutions by IMCB-A! Joint Service Platform @IMCB

Optimised Pathology Workflow, Empower Pathologists & Researchers with Advanced Analytic Capability

IMCB-A! Joint Service Platform @ IMCB offers a complete digital pathology approach from scanning to image analysis. The service platform is unique in that it can optimize pathology workflows, give pathologists and researchers advanced analysis capabilities, and better support clinical decisions and accelerate drug discovery.


Key Services

  • Specimen staining with fully automatic multiplex IHC stainer
  • Provides whole slide imaging scans and tissue microarrays (TMA) imaging scans
  • Available staining methods are InSituPlex Kit (Ultivue) and Opal Kit (Perkin Elmer)
  • Hematoxylin and eosin (H&E) bright field scanning objectives with 20x or 40x magnifications
  • Immunohistochemistry (IHC) bright field scanning objectives with 20x or 40x magnifications
  • Multiple fluorescence immunohistochemistry (IHC) scans with 20x or 40x magnification of objective lens


Key Techniques

  • H&E and IHC image quantification and analysis


Key Techniques

  • Quantitative cell phenotype analysis performed on multiple images includes:
  1. Prostate Cancer
  2. Breast Cancer
  3. Endometrial Cancer


A!maginostic: AI powered Imaging analytics for Diagnosis

A!maginostic is an A*STAR IMCB spin-off company established in 2017. We are committed to advance quantitative digital pathology image analysis and reliable diagnostic solutions in both academic research and clinical application. The core technology team has extensive experience of designing and prototyping accurate, efficient and powerful solutions for cellular and digital pathology imaging informatics.

We integrate methodologies from multiple fields such as signal processing, image processing and computer vision, optimization, machine learning, pattern recognition, mathematical modeling, artificial intelligence (AI), deep learning (DL), in collaboration with pathologists, oncology Scientists and cell biologists, etc. Our goal is to provide patients/clinicians with efficient, accurate and robust digital pathology algorithms/solutions and improve healthcare for the public.

A!maginostic and A * STAR's Institute of Molecular and Cell Biology (IMCB) have established a joint laboratory of excellence in 2019. The collaboration will use image processing and artificial intelligence / machine learning to revolutionize pathology practices and provide more accurate cancer diagnostic assays.